NASDAQ:CPRX Catalyst Pharmaceuticals (CPRX) Stock Price, News & Analysis $19.60 -0.22 (-1.11%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$19.26▼$19.9650-Day Range$15.19▼$20.7452-Week Range$11.55▼$20.87Volume736,447 shsAverage Volume1.26 million shsMarket Capitalization$2.32 billionP/E Ratio36.30Dividend YieldN/APrice Target$29.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Catalyst Pharmaceuticals alerts: Email Address Catalyst Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside50.5% Upside$29.50 Price TargetShort InterestBearish4.93% of Float Sold ShortDividend StrengthN/ASustainability-1.99Upright™ Environmental ScoreNews Sentiment1.14Based on 6 Articles This WeekInsider TradingSelling Shares$4.14 M Sold Last QuarterProj. Earnings Growth18.68%From $1.82 to $2.16 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.86 out of 5 starsMedical Sector23rd out of 910 stocksPharmaceutical Preparations Industry7th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingCatalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCatalyst Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Catalyst Pharmaceuticals' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.93% of the float of Catalyst Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCatalyst Pharmaceuticals has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Catalyst Pharmaceuticals has recently increased by 4.77%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldCatalyst Pharmaceuticals does not currently pay a dividend.Dividend GrowthCatalyst Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCatalyst Pharmaceuticals has received a 52.55% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Amifampridine" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Catalyst Pharmaceuticals is -1.99. Previous Next 3.4 News and Social Media Coverage News SentimentCatalyst Pharmaceuticals has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Catalyst Pharmaceuticals this week, compared to 4 articles on an average week.Search Interest10 people have searched for CPRX on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Catalyst Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Catalyst Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,139,372.00 in company stock.Percentage Held by Insiders11.00% of the stock of Catalyst Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions79.22% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Catalyst Pharmaceuticals' insider trading history. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Catalyst Pharmaceuticals are expected to grow by 18.68% in the coming year, from $1.82 to $2.16 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Pharmaceuticals is 36.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 128.02.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Pharmaceuticals is 36.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 115.16.Price to Earnings Growth RatioCatalyst Pharmaceuticals has a PEG Ratio of 3.30. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCatalyst Pharmaceuticals has a P/B Ratio of 3.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Catalyst Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About Catalyst Pharmaceuticals Stock (NASDAQ:CPRX)Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Read More CPRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CPRX Stock News HeadlinesAugust 24, 2024 | insidertrades.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Director David S. Tierney Sells 15,000 SharesAugust 23, 2024 | insidertrades.comInsider Selling: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells 150,000 Shares of StockSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… August 14, 2024 | insidertrades.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells $664,188.36 in StockSeptember 2, 2024 | americanbankingnews.comCatalyst Pharmaceuticals, Inc. Forecasted to Earn Q3 2024 Earnings of $0.45 Per Share (NASDAQ:CPRX)August 29, 2024 | americanbankingnews.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Recommendation of "Buy" from BrokeragesAugust 28, 2024 | americanbankingnews.comInsider Selling: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells $3,052,500.00 in StockAugust 20, 2024 | globenewswire.comCatalyst Pharmaceuticals to Participate in Upcoming Investor ConferencesSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… August 16, 2024 | marketwatch.comCatalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitorsAugust 14, 2024 | finance.yahoo.comCatalyst Pharmaceuticals' (NASDAQ:CPRX) Anemic Earnings Might Be Worse Than You ThinkAugust 8, 2024 | markets.businessinsider.comCPRX Stock Earnings: Catalyst Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024August 7, 2024 | globenewswire.comCatalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 6, 2024 | marketwatch.comCatalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitorsJuly 24, 2024 | msn.comCatalyst sells Canadian rights to Duchenne drug to Kye PharmaJuly 24, 2024 | globenewswire.comCatalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in CanadaJuly 23, 2024 | marketwatch.comCatalyst Pharmaceuticals Inc. stock rises Monday, still underperforms marketJuly 22, 2024 | globenewswire.comCatalyst Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 7, 2024See More Headlines Receive CPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Catalyst Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CPRX CUSIPN/A CIK1369568 Webwww.catalystpharma.com Phone(305) 420-3200Fax305-529-0933Employees80Year Founded2002Price Target and Rating Average Stock Price Target$29.50 High Stock Price Target$34.00 Low Stock Price Target$23.00 Potential Upside/Downside+50.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$0.54 Trailing P/E Ratio36.30 Forward P/E Ratio10.77 P/E Growth3.3Net Income$71.41 million Net Margins15.69% Pretax Margin21.53% Return on Equity27.77% Return on Assets23.68% Debt Debt-to-Equity RatioN/A Current Ratio5.14 Quick Ratio4.94 Sales & Book Value Annual Sales$434.48 million Price / Sales5.33 Cash Flow$1.99 per share Price / Cash Flow9.85 Book Value$5.13 per share Price / Book3.82Miscellaneous Outstanding Shares118,115,000Free Float105,122,000Market Cap$2.32 billion OptionableOptionable Beta0.70 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Richard John Daly M.B.A. (Age 63)President, CEO & Director Comp: $68.12kDr. Steven R. Miller Ph.D. (Age 62)Executive VP, COO & Chief Scientific Officer Comp: $884.7kDr. Gary Ingenito M.D. (Age 68)Ph.D., Chief Medical & Regulatory Officer Comp: $811.39kMr. Jeffrey Del Carmen (Age 53)Executive VP & Chief Commercial Officer Comp: $799.82kMr. Michael W. Kalb CPA (Age 53)Executive VP, Treasurer & CFO Ms. Mary ColemanVP & Head of Investor RelationsMr. Brian Elsbernd J.D. (Age 60)Chief Compliance Officer & Chief Legal Officer Comp: $311.42kMr. Pete Curry Sr.Vice President of SalesDr. Stanley Iyadurai M.D.Ph.D., Senior Vice President of Medical Affairs & Drug DiscoveryDr. Preethi Sundaram Ph.D. (Age 48)Chief Strategy Officer Comp: $511.25kMore ExecutivesKey CompetitorsANI PharmaceuticalsNASDAQ:ANIPProgenics PharmaceuticalsNASDAQ:PGNXDURECTNASDAQ:DRRXSyros PharmaceuticalsNASDAQ:SYRSCue BiopharmaNASDAQ:CUEView All CompetitorsInsiders & InstitutionsPVG Asset Management CorpBought 11,786 shares on 8/22/2024Ownership: 0.010%David S TierneySold 15,000 sharesTotal: $301,500.00 ($20.10/share)Steve MillerSold 150,000 sharesTotal: $3.05 M ($20.35/share)Point72 Asset Management L.P.Bought 200,370 shares on 8/19/2024Ownership: 0.523%Quarry LPBought 10,284 shares on 8/16/2024Ownership: 0.014%View All Insider TransactionsView All Institutional Transactions CPRX Stock Analysis - Frequently Asked Questions How have CPRX shares performed this year? Catalyst Pharmaceuticals' stock was trading at $16.81 at the beginning of the year. Since then, CPRX stock has increased by 16.6% and is now trading at $19.60. View the best growth stocks for 2024 here. How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) announced its quarterly earnings results on Wednesday, August, 7th. The biopharmaceutical company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.13. The biopharmaceutical company had revenue of $122.71 million for the quarter, compared to analysts' expectations of $111.76 million. Catalyst Pharmaceuticals had a net margin of 15.69% and a trailing twelve-month return on equity of 27.77%. Who are Catalyst Pharmaceuticals' major shareholders? Catalyst Pharmaceuticals' top institutional investors include Deerfield Management Company L.P. Series C (7.73%), Dimensional Fund Advisors LP (2.54%), Pacer Advisors Inc. (2.51%) and Renaissance Technologies LLC (1.84%). Insiders that own company stock include Patrick J Mcenany, Steve Miller, Donald A Denkhaus, Philip H Coelho, Brian Elsbernd, Gary Ingenito, Alicia Grande, Carmen Jeffrey Del, Molly Harper and Preethi Sundaram. View institutional ownership trends. How do I buy shares of Catalyst Pharmaceuticals? Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Catalyst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU) and Verastem (VSTM). This page (NASDAQ:CPRX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
